Reaction
Mantle Cell Lymphoma reporting signals
As of the last recalculation, Mantle Cell Lymphoma appears in 1,497 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is BENDAMUSTINE HCL (PRR 97.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bendamustine Hcl | 101 | 97.0 | 97.7 |
| Ibrutinib | 389 | 90.1 | 90.5 |
| Bendamustine Hydrochloride | 52 | 62.5 | 62.8 |
| Acalabrutinib | 44 | 52.0 | 52.2 |
| Venetoclax | 191 | 49.3 | 49.4 |
| Rituximab | 430 | 39.3 | 39.4 |
| Bortezomib | 212 | 38.2 | 38.3 |
| Cytarabine | 138 | 35.1 | 35.2 |
| Melphalan | 35 | 21.9 | 21.9 |
| Doxorubicin | 124 | 21.0 | 21.0 |
| Melphalan Hydrochloride | 35 | 19.9 | 19.9 |
| Doxorubicin Hydrochloride | 45 | 19.7 | 19.7 |
| Obinutuzumab | 19 | 16.3 | 16.3 |
| Cyclophosphamide Injection, Solution | 168 | 14.7 | 14.7 |
| Cyclophosphamide | 168 | 14.7 | 14.7 |
| Cyclophosphamide For Injection | 168 | 14.7 | 14.7 |
| Thiotepa | 9 | 13.2 | 13.2 |
| Valacyclovir | 32 | 10.9 | 10.9 |
| Etoposide | 54 | 10.6 | 10.6 |
| Lenalidomide | 257 | 10.0 | 10.0 |
| Vincristine Sulfate | 20 | 9.6 | 9.6 |
| Fludarabine Phosphate | 26 | 9.3 | 9.3 |
| Cisplatin | 37 | 6.7 | 6.7 |
| Ifosfamide | 9 | 5.9 | 5.9 |
| Eltrombopag Olamine | 9 | 5.5 | 5.5 |
| Pemetrexed | 8 | 5.2 | 5.2 |
| Romiplostim | 5 | 4.6 | 4.6 |